flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Kidney and Survival Benefits of

Resources Continuous Intravenous Vitamin C in the Cancer Treatment: Reevaluation of a Phase I Clinical Study (2019) Changes in the rate of PSA progression and the level of alkaline phosphatase during high dose vitamin C treatment of patients with prostate cancer Suppression of Alkaline Phosphatase in Prostate Cancer Patients by High Dose Intravenous Vitamin C Treatment: Three Cases High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report [VIEW MORE ARTICLES] [VIEW RESEARCH STUDIES] Learn More Are you a doctor or medical professional wanting to learn more about using IV Vitamin C in your practice

Verrotti A, Trotta D, Morgese G, et al

Expect to see the most significant changes after three to four months of consistent use alongside solid lifestyle foundations

PMID: 125 FaucherQJardouMBrossierCPicardNMarquetPLawsonR